In today's episode, we chat with Dr. Peter Rahfeld, Chief Scientific Officer at ABOzymes Biomedical, a startup based in Vancouver currently incubating at the University of British Columbia.
If you can believe this… ABOzymes is working to realize a world where blood types are no longer a constraint for those receiving a life-saving blood transfusion or organ transplant.
In short: they’re making blood types obsolete.
In our chat, Dr. Rahfeld and I also explore:
✅ What it’s like to merge academia, research and business to produce a startup
✅ Why it’s critical to have a growth mindset and be open to continual learning
✅ How to envision a product and a market when you’re in uncharted territory, business-wise
...and much more.
If you enjoyed it, please subscribe to The BC Startup Show and leave us a review.
Our Guest and Resources We Mentioned
Learn more about ABOzymes Biomedical: https://www.abozymes.com/
ABOzymes on Twitter: https://twitter.com/ABOzymes
ABOzymes on LinkedIn: https://www.linkedin.com/company/abozymes-biomedical-inc